Skip to main content
ASCPT 2025 Annual Meeting Main banner

Jeffrey A. Moscow, MD (he/him/his)

Retired
Investigational Drug Branch, National Cancer Institute

Dr Moscow is a graduate of Harvard University and of the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, National Cancer Institute (NCI). In 1997, Dr. Moscow moved from NCI to the University of Kentucky (UK), where he was Children’s Miracle Network Professor of Pediatrics, Chief of Pediatric Hematology-Oncology, Vice Chair of Pediatrics, and co-leader of the Experimental Therapeutics Program of the Markey Cancer Center. As a clinician, he was included for many years on both Top Doctors and Best Doctors lists. Dr. Moscow joined the National Cancer Institute's (NCI) Investigational Drug Branch (IDB) of the Cancer Therapy Evaluation Program (CTEP) in 2014. IDB oversees the early clinical development of novel anticancer agents in collaboration with pharmaceutical industry partners and academic oncologists. Dr. Moscow became chief of IDB in 2018 and retired in 2023. At NCI he provided leadership for both preclinical (PDXNet) and clinical (ComboMATCH trial and the Experimental Therapeutics Clinical Trials Network) research initiatives. He also led a research laboratory effort for over two decades focused on cancer drug resistance, and is an author of over 100 peer-reviewed publications and book chapters. He is now a Special Volunteer at the National Cancer Institute, Professor Emeritus at the University of Kentucky, and is a consultant to academic institutions and pharmaceutical industry.

Presentation(s):